Silent Signals: How Stroke Rewires Brain Astrocytes to Accelerate Glioma Growth

A stroke is one of the most devastating events the brain can endure, killing neurons and triggering a cascade of inflammation and tissue repair. But a new study published in Nature Cancer suggests that the aftermath of a stroke may do far more than leave scar tissue behind. Researchers led by Hyun Kyoung Lee at Baylor College of Medicine report that ischemic stroke can actively reshape the brain’s environment in ways that promote the growth and invasion of glioma, the most common and lethal form of adult brain cancer. The findings offer a mechanistic explanation for a puzzling epidemiological observation that has circulated in the clinical literature for years: patients with a history of stroke appear to face an elevated risk of developing brain tumors.

The team set out to test whether the connection between brain injury and glioma was more than coincidence. Drawing on population-based studies that had linked stroke, traumatic brain injury, and other neurological insults to increased brain cancer incidence, the researchers engineered a series of preclinical models in which mice experienced an induced ischemic stroke before or after glioma cells were introduced into the brain. The results were striking. In both patient-derived xenograft models and genetically engineered high-grade glioma models, tumors implanted into brains that had experienced a stroke grew larger, invaded more aggressively into surrounding cortical tissue, and in one model spread significantly further into the injured cortex compared with tumors in sham-operated controls. Mice with stroke-primed gliomas also showed reduced overall survival, and even a slower-growing low-grade glioma model showed increased tumor cellularity after stroke exposure.

Crucially, the phenomenon was not limited to mice. When the researchers compared transcriptional profiles from human high-grade glioma samples in The Cancer Genome Atlas with gene expression data from patients who had suffered stroke, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and schizophrenia, they found that stroke showed the strongest molecular overlap with glioma. Genes that were coordinately upregulated or downregulated in both conditions pointed to a shared injury-response program, suggesting that the biology the team uncovered in mice has echoes in human disease. Single-cell RNA sequencing and spatial transcriptomics of tumor-bearing brains then revealed what that program actually involved: a wholesale remodeling of the tumor microenvironment at the invasive edge of the tumor.

At the heart of the discovery is a specialized astrocyte population the authors call tumor-associated astrocytes, or TAAs. Astrocytes are star-shaped glial cells that normally support neurons, regulate neurotransmitters, and maintain the blood-brain barrier. In healthy tissue, they communicate through rhythmic surges of intracellular calcium ions, or Ca2+ activity, which coordinate their metabolic and signaling functions. The team found that in the stroke-primed tumors, a distinct subset of these astrocytes emerged at the tumor’s invasive front with a remarkable property: their spontaneous calcium signaling was markedly dampened. The researchers dubbed this population stroke-induced tumor-associated astrocytes, and their reduced calcium oscillations appeared to be a functional change, not merely a byproduct of injury, because astrocytes located far from the stroke lesion retained normal activity.

Why would quieter astrocytes help a tumor? The answer, the study shows, lies in the immune landscape of the glioma. Using computational tools that map ligand-receptor communication between cell types, the researchers found that the calcium-suppressed astrocytes expressed elevated levels of CCL2, a chemokine well known for attracting immune cells bearing the CCR2 receptor. This signal acted as a beacon for tumor-associated microglia and macrophages, collectively called TAMs, which accumulated in the invasive margin of stroke-primed tumors. TAMs are a double-edged sword in brain cancer: while they can theoretically attack tumor cells, they more often nurture them, secreting growth factors, suppressing anti-tumor immunity, and paving the way for invasion. The density of these myeloid cells in the stroke-remodeled environment gave the tumor exactly the kind of accomplice it needed to expand into injured tissue.

The causal chain was confirmed through a series of elegant perturbation experiments. When the researchers pharmacologically depleted TAMs in stroke-primed mice using a CSF1R inhibitor, the stroke-driven acceleration of tumor growth was largely abolished. Similarly, when they used engineered receptor tools to artificially restore calcium activity in the tumor-associated astrocytes, either by activating Gq-coupled designer receptors or by other calcium-restoring manipulations, the astrocytes resumed a more normal signaling profile, CCL2 expression fell, macrophage recruitment declined, and tumor progression slowed. These reciprocal experiments demonstrate that neither the astrocyte change nor the macrophage influx alone is sufficient; it is the astrocyte-to-macrophage signaling axis that transmits the stroke injury into tumor-promoting action.

The team then traced the molecular switch that silences astrocyte calcium signaling after stroke. Their search converged on SLC4A4, a gene encoding the electrogenic sodium-bicarbonate cotransporter NBCe1, a protein that regulates intracellular pH by moving bicarbonate across the cell membrane. The group had previously shown that astrocytic SLC4A4 helps maintain blood-brain barrier integrity through a CCL2-CCR2 pathway, making it a plausible candidate in the current context. In the new study, single-cell analysis revealed that SLC4A4 was enriched in tumor-associated astrocytes, and that its expression correlated with robust calcium activity. When the researchers genetically deleted Slc4a4 specifically from astrocytes in mice, the astrocytes’ calcium signaling collapsed, CCL2 expression rose, TAMs flooded into the tumor, and gliomas grew faster and larger across two independent models. Conversely, overexpressing SLC4A4 in astrocytes boosted their calcium activity and suppressed tumor growth, even blunting the stroke-induced acceleration of cortical invasion.

The genetic logic of the pathway was sealed with combination experiments. When the researchers deleted Slc4a4 together with Ccl2 from astrocytes, or deleted Slc4a4 while simultaneously depleting TAMs pharmacologically, the aggressive tumor phenotype caused by Slc4a4 loss was reversed. In other words, the entire tumor-promoting effect of a calcium-silenced astrocyte depends on its ability to recruit myeloid cells through CCL2. Interrupt that recruitment, and the tumor loses its stroke-widened path of invasion. Computational modeling of cell-cell communication reinforced this conclusion, showing that SLC4A4-low astrocytes behave as dominant signaling senders toward tumor cells, with a dense web of ligand-receptor interactions that disappears when the pathway is genetically or pharmacologically interrupted.

Beyond its immediate findings, the study carries broader implications for how scientists think about the relationship between brain injury and cancer. Recent work from other groups has shown that gliomagenesis can mimic an injury-response program and that injury can prime mutation-bearing glial cells for malignant dedifferentiation, while neuronal activity itself has been shown to drive glioma progression through secreted factors. The new results add a precise mechanistic layer to this emerging picture: the brain’s own first responders to injury, the astrocytes, can be reprogrammed into a state that is permissive, even hospitable, to malignant growth. Calcium signaling, long studied in the context of synaptic support and gliotransmission, now appears to function as a tumor-suppressive gatekeeper in the glioma microenvironment.

Therapeutically, the work suggests several points of intervention. If clinical studies confirm that stroke history reshapes the microenvironment of human gliomas, then patients with prior strokes might benefit from intensified surveillance, and treatments aimed at restoring astrocyte calcium homeostasis, blocking CCL2-mediated myeloid recruitment, or depleting tumor-promoting macrophages could complement existing surgical, radiation, and immunotherapeutic approaches. Compounds that modulate bicarbonate transport or pH regulation in astrocytes, or chemokine-blocking agents already in development for other diseases, could find new applications in neuro-oncology. For now, the study stands as a vivid demonstration that the boundary between neurological disease and cancer is thinner than once believed, and that the injured brain can become an unwitting accomplice to the tumors that grow within it.

Subject of Research: How stroke-induced changes in astrocyte calcium signaling and macrophage recruitment promote glioma progression

Article Title: Stroke drives glioma progression through the emergence of tumor-associated astrocytes with reduced Ca2+ activity

Article References: Ye, Q., Madamba, C., Woo, J., Choy, T. J., Wheeler, K. F., Zhan, J., Cristobal, C. D., Spjut, C., Shin, D., Jo, J., Ailani, R. R., Smith, J., Latha, K., Harmanci, A. S., Yalamanchili, H. K., Gallo, M., Yun, K., Reshetnyak, Y. K., Kim, E., … Lee, H. K. (2026). Stroke drives glioma progression through the emergence of tumor-associated astrocytes with reduced Ca2+ activity. Nature Cancer. https://doi.org/10.1038/s43018-026-01238-8

Image Credits: AI Generated

DOI: 10.1038/s43018-026-01238-8

Keywords: glioma, stroke, astrocytes, calcium signaling, tumor-associated macrophages, CCL2, SLC4A4, tumor microenvironment, brain injury, Nature Cancer, neuro-oncology, invasion